builderall

CONFERENCE INFORMATION

CONFERENCE DESCRIPTION

The Masters in Therapeutic Oncology Summit- Genitourinary (GU) Edition (MaTOS-GU) is a very innovative event that offers new approaches to the challenges in learning and updating current treatments in GU tumors. The summit is mainly a gathering of key opinion leaders (KOLS) in the area of GU oncology that meet for 2 full days to review the latest information and developments in GU oncology sharing their research among themselves and discussing challenging situations in the real world when the knowledge is applied to daily practice.

Topics go from early molecular diagnosis and testing to epigenomics and the challenge to find a role for minimal residual disease (MRD) and its application in patients that have completed therapy from surgery to systemic therapy. The idea is also discussing the role of multidisciplinary approach to early stage GU cancers and also find a multidisciplinary role in advanced cancers where there are still opportunities to help patients with current interventions from radiotherapy and other local interventions to palliative care.

It’s essential to expend discussions and roundtables discussing the current role of immunotherapy in cancer and the development of targeted therapy for these tumors too. Current challenges include the development of new checkpoint inhibitors and better biomarkers to improve immunotherapy response. Targeted therapy needs also to improve with the discovery of new actionable genetic aberrations and the development of new agents to overcome tyrosine kinase inhibitor resistance. In both cases also immunotherapy and targeted therapy have the unmet need of the lack of biomarkers to assess therapy response and duration of therapy, something that deserves to be investigated and review in view of the current developments in cancer.

It's important also to learn from our industry partners the status in the development of new drugs and the review of the most current pipelines and clinical trials coming to the clinic and to interact with our clinical researchers to develop more concepts or ideas to increase the number of clinical trials and to find ways that we can accelerate the development of new agents.

LEARNER OBJECTIVES

Upon conclusion of this summit, participants will be able to:

  • Analyze the latest discoveries in genetics and epigenomics in GU cancer, including diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotherapy.

  • Identify the latest drug developments in GU oncology by an expert panel of senior investigators and KOLs in the field.

  • Distinguish the importance of GU cancer screening and successful implementation, including programs not only based on imaging but also on liquid biopsies and other technologies.

  • Understand the multidisciplinary application of new developments in GU cancer to the current standards of care.

  • Evaluate information on new products and developments in GU cancer care for best utilization.